Noradrenalin Fresenius Kabi (Noradrenaline Tartrate)

Noradrenaline binds directly to alpha‑1 adrenergic receptors causing peripheral vasoconstriction, and to beta‑1 receptors in the heart, which increases myocardial contractility and heart rate. This dual action raises systemic vascular resistance and cardiac output, improving blood pressure in shock states.

The dose is individualized. A prescriber determines the starting infusion rate and titrates it based on the patient’s blood pressure and clinical response, following institutional protocols and continuous monitoring.

Safety data are limited. The product should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under strict medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative is dopamine, which has dose‑dependent effects on dopaminergic, beta‑ and alpha‑receptors. Noradrenaline provides more predictable vasoconstriction with less tachycardia, making it the preferred first‑line agent for most forms of septic shock and severe hypotension.

The solution should be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

It is given as an intravenous infusion, typically through a central venous catheter for prolonged use. The infusion is started at a low rate and titrated to achieve target blood pressure, with continuous hemodynamic monitoring.

Serious risks include severe hypertension, myocardial ischemia, and tissue necrosis at the infusion site if extravasation occurs. Prompt recognition and immediate intervention are essential to prevent irreversible damage.

Patients with known hypersensitivity to norepinephrine or any component of the formulation should not receive the product. Caution is also advised in individuals with pheochromocytoma, uncorrected hypovolemia, or severe peripheral vascular disease.